J&J: FDA approval for Edurant Ped in HIV

(CercleFinance.com) - Johnson & Johnson announced today that the US FDA has approved Edurant Ped (rilpivirine) for the treatment of HIV-1 in combination with other antiretroviral (ARV) therapies in treatment-naive children aged at least 2 years and weighing between 14 and 25 kg.


This approval builds on Johnson & Johnson's long-standing commitment to ensuring that people living with HIV, including children, have treatment options that can work for them.

Although the population of young children living with HIV is small, additional treatment options remain essential to ensure that every person living with HIV can benefit from a treatment regimen that works for them, Johnson & Johnson said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.